From standard of care
to the frontier.
Once bladder cancer invades muscle, treatment aims at cure and must address both the bladder and the rest of the body. Options are shaped by stage, whether cisplatin chemotherapy is possible, and whether keeping the bladder is realistic.
How to read this page. This is an educational map of how treatment decisions are generally approached, not a recommendation, and not a description of any individual’s situation. Position on the scale reflects clinical maturity and how an option is reached, not how effective or promising it is. Protocol outlines show structure and sequence only; doses, schedules, and eligibility are determined by a care team.
The escalation scale
Move along the scale to see what exists at each level of clinical maturity, what unlocks it, and what the protocol looks like. Every option names the guideline or trial it rests on.
Foundation
The backbone of curative treatment: removing and staging the tumour, chemotherapy before surgery for those who can receive it, surgery to remove the bladder, and bladder-preserving chemoradiation as an established alternative.
How it is accessed: Offered as routine care at centres that treat bladder cancer.
How an option gets chosen
Treatment is a sequence of decisions, each one waiting on a test result. Pick a starting point and walk the path: choose the finding at each step to see which options it opens and what question comes next.
- At diagnosis
Has the cancer invaded muscle, and has it spread?
Two findings define everything that follows. TURBT pathology establishes whether cancer reached the muscle layer, and imaging establishes whether it has spread beyond the bladder and regional nodes. Non-muscle-invasive disease is treated on a different pathway entirely.
Tests that inform thisTURBT pathologyBladder tissue removed through the urethraStaging imagingImaging of abdomen, pelvis, chest, and upper urinary tractVariant histologyTumour tissueBasis: NCCN Guidelines: Bladder Cancer; AUA/SUO and EAU guidelines
The tests behind the decisions
Nearly every branch above depends on a result. These are the tests that produce them, what each one decides, and how established it is.
| Test | Sample & method | What it decides | When | Status |
|---|---|---|---|---|
| TURBT pathologyTURBT pathology | Bladder tissue removed through the urethraPathologist review of resected tissue | Whether cancer has invaded the muscle layer, its grade, and whether a variant type is present. This is the finding that defines the disease.Limitation: Sampling can under-stage disease if muscle is not adequately represented; a repeat resection is sometimes needed. | At diagnosis, before treatment planning | Routinely used |
| Staging imagingStaging imaging | Imaging of abdomen, pelvis, chest, and upper urinary tractCT urography, sometimes MRI of the bladder, and chest imaging; PET in selected cases | Whether disease is confined to the bladder and regional nodes or has spread, which separates curative treatment from treatment aimed at control. | At diagnosis, and again if recurrence is suspected | Routinely used |
| Cisplatin eligibilityCisplatin eligibility assessment | Blood tests and clinical assessmentKidney function, hearing, nerve function, heart function, and performance status | Whether cisplatin-based chemotherapy can be given safely. This is one of the highest-consequence decisions in the pathway, because the strongest evidence for treatment before surgery rests on cisplatin.Limitation: Criteria are consensus-based, and borderline cases are judged individually. | Before deciding whether chemotherapy comes before surgery | Routinely used |
| Surgical pathologySurgical pathology after cystectomy | Bladder and lymph nodes removed at surgeryPathologist review of the surgical specimen | How much cancer remained after any pre-surgery treatment, and whether lymph nodes are involved. This determines whether further treatment is offered after surgery. | After radical cystectomy | Routinely used |
| Variant histologyVariant histology review | Tumour tissuePathologist assessment, sometimes with expert second review | Whether the tumour contains a variant type, which can influence how aggressive treatment should be and whether standard approaches apply.Limitation: Recognition varies between pathologists; specialist review is often recommended. | At diagnosis, on the resection specimen | Used in selected circumstances |
| FGFR3FGFR2/FGFR3 alteration testing | Tumour tissue, or blood in some assaysNext-generation sequencing or a targeted assay | Whether an FGFR-directed oral targeted therapy is an option in advanced or metastatic disease after prior treatment.Limitation: Relevant to advanced disease options; a negative result does not affect curative-intent treatment. | When advanced or metastatic disease is being treated, not usually needed for localised disease | Used in selected circumstances |
| HER2HER2 expression | Tumour tissueImmunohistochemistry | Whether a HER2-directed antibody-drug conjugate may apply under a tumour-agnostic approval, for strongly HER2-positive tumours.Limitation: Applies to a minority of tumours. | In advanced disease, when later options are being considered | Used in selected circumstances |
| Genomic profilingTumour genomic profiling, MSI and TMB | Tumour tissue, sometimes with bloodNext-generation sequencing panel reporting mutations, microsatellite instability, and tumour mutational burden | Whether a tumour-agnostic immunotherapy or targeted option applies, and whether a biomarker-matched trial fits.Limitation: Many findings are not currently actionable in bladder cancer. | Commonly in advanced disease, or when considering a trial | Used in selected circumstances |
| ctDNACirculating tumour DNA | BloodSensitive sequencing for tumour DNA after treatment | In studies, whether cancer remains detectable after surgery, and whether treatment after surgery can be guided or de-escalated by that result.Limitation: Whether to act on a ctDNA result in bladder cancer is the question current trials exist to answer. | After surgery, largely within trials | Emerging |